Attachment 1 - VA Product List.xlsx

This is a Product List attachment to a Request for Information (RFI) issued by the Department of Veterans Affairs National Acquisition Center for U.S.-Produced Pharmaceuticals under Executive Order 13944. The RFI seeks market research to identify sources capable of supplying pharmaceutical products with U.S.-based manufacturing and critical inputs. The VA has identified 47 pharmaceutical products across multiple categories requiring vendor capability assessment, including injectable medications such as Dexamethasone, Fentanyl Citrate, Heparin Sodium, Hydromorphone, Lorazepam, Midazolam, Morphine Sulfate, Naloxone, Octreotide Acetate, Ondansetron, Phenylephrine, and various saline and support medications, along with select oral solutions. Annual requirements range from 34 units to 218,860 units depending on the specific product formulation and package size.

Respondents are required to provide detailed information for each product including the origin of Key Starting Materials (KSM), Active Pharmaceutical Ingredient (API) origin, packaging material origin, final drug manufacturing origin, manufacturer name, supply capability confirmation, and additional comments. While the RFI does not guarantee a subsequent solicitation or commitment to award contracts, the VA emphasizes its highest priority as identifying fully U.S.-produced pharmaceuticals that meet Executive Order 13944 criteria, with secondary value placed on products incorporating any U.S. manufacturing activity such as domestic production of critical inputs, intermediate manufacturing steps, or final processing. This market research effort aims to assess vulnerabilities and potential disruptions in the current pharmaceutical supply chain to mitigate patient safety risks.